Pfizer secures two-year extension on Vyndamax patent, delaying competition

Pfizer announced it has obtained an extension that pushes back the start of generic competition for its heart-failure drug Vyndamax (tafamidis) by about two years.

Vyndamax ranks among Pfizer’s top three revenue-generating medicines and vaccines, making the extension financially significant for the company.

The delay stems from a successful patent strategy that adds additional protection, allowing Pfizer to maintain market exclusivity longer.

Analysts note that the extra protection could bolster Pfizer’s earnings outlook, though the broader market impact remains limited to the drug’s niche indication.